Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Chairman's AGM Address

26 November 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, provides a copy of the Chairman's address, which will be delivered at the Company's Annual General Meeting today.

ADDRESS BY THE CHAIRMAN, SERGIO DUCHINI

Ladies and Gentlemen, Shareholders,

Welcome to the Annual General Meeting of Neurizon Therapeutics Limited.

Thank you for joining us, whether you are attending in person or virtually. During this address, I will outline the considerable progress Neurizon has made over the last year, then take you through each resolution.

Purpose and thanks

I would like to take this opportunity to reiterate the Company's key purpose, which remains very clear:

> *To lead the development of neurodegenerative disease treatments towards a promising new horizon for patients.*

To the ALS community, the patients, carers, clinicians, and advocates we thank you. Your courage and resilience is not only inspirational, but pivotal to the broader plight against ALS, as well our focus and discipline as a Company.

With that, I want to acknowledge and thank Dr Michael Thurn and our executive team for their leadership and tireless commitment this year. Your execution across regulatory, clinical, CMC and capital planning has been critical to our achievements and momentum. I also extend thanks to my fellow Directors for their diligence, skill, oversight and support.

The Board's ongoing challenge to strategies and continued stewardship have strengthened our decision-making through this period, underpinning pleasing operational momentum.

Board Observer Appointment

This year also marked an important strengthening of our governance framework with the appointment of Ms Justine Conway, Global Head of Business Development at Elanco, as a Board Observer.

Ms Conway brings more than two decades of global experience across animal health, pharmaceuticals, and investment banking. Her expertise spans business development, strategic partnering, M&A, external innovation, and capital markets — capabilities that align extremely well with Neurizon's transition toward late-stage development and commercial readiness.

Her appointment reflects the strength of our ongoing partnership with Elanco following our exclusive global licence agreement for Monepantel, the active pharmaceutical ingredient in NUZ-001.

As Board Observer, Ms Conway participates in all Board and committee meetings without voting rights, contributing valuable strategic insight as we progress toward commencement of the HEALEY ALS Platform Trial and prepare for global commercialisation.

Year in review — progress with discipline

Over the past 12 months, the Company has made steady progress in the execution of our strategy. This has included:

- **Regulatory**: The FDA clinical hold on NUZ-001 has now been lifted. We are aligned to enter the HEALEY ALS Platform Trial in this quarter, subject to final protocol completion and site activations, which are expected in the very near term.
- **Preclinical:** We are pleased with the progress of our preclinical programme that highlights promise for NUZ-001 in other neurodegenerative diseases. Additional studies reinforced the proposed mechanism (selective mTOR modulation and autophagy), showing neuroprotection and reductions in TDP-43–related pathology; new datasets were recently presented at NEALS conference in the USA and are informing our biomarker plan (e.g., STMN2 and autophagy markers) and Phase 2 dose rationale.
- **Clinical**: The 12-month open-label extension met its primary safety objective at the intended Phase 2 dose and showed directional signals on function and respiration versus matched historical controls.
- **Enablement**: Our global licence and data-access agreement with Elanco strengthens non-clinical and CMC foundations, de-risks our regulatory pathway and reduces the overall time to market through manufacturing readiness and supply; GMP tablet registration batches with Catalent have been finalised, marking a key milestone towards commercialisation and FDA NDA regulatory submission.
- **Capital & platform**: We completed a ~$5.2m placement, progressed R&D Tax Incentive claims (including Advanced & Overseas Findings), secured an OTCQB quotation to broaden reach, appointed leading US consultancy Integrous Communications to further strengthen our US presence, and secured a key Australian patent approval which ensures unified global IP protection through to May 2041.

Neurizon's four-pillar strategy underpins our near-term priorities:

Neurizon's four-pillar strategy forms the foundation of how we create value — for patients, partners, and shareholders alike. These pillars bring clarity and focus to our mission, aligning our resources and execution around the areas that matter most: accelerating patient access, driving clinical progress, broadening therapeutic impact, and delivering commercial success.

Each pillar defines a critical dimension of Neurizon's journey — from advancing our science and expanding our reach, to strengthening the foundations that will support long-term growth and shareholder value. Together, they represent a balanced strategy that bridges our purpose with performance.

1. **Accelerating patient hope and access:** We are committed to making therapies available as early as possible through regulatory pathways like Orphan Drug Designation in the U.S., Special Access Schemes in Australia, and working closely with patient advocacy groups across the world.
2. **Driving clinical progress with NUZ-001:** Through initiatives like the HEALEY ALS Platform Trial, we are focused on generating robust clinical evidence that can demonstrate real benefit for all patients.
3. **Unlocking the potential of Neurizon to address the high unmet need in neurodegenerative diseases:** We are focussed on extending NUZ-001's impact across a broader range of neurodegenerative diseases to act as a platform therapy targeting common proteinopathies to diversify and de-risk our pipeline.
4. **Delivering commercial readiness and stakeholder value:** Building a strong foundation for long-term commercial success through collaborations and commercial readiness for international

markets. Aligning science and execution to bring NUZ-001 to market while unlocking value for all stakeholders.

With that, I would like to extend my sincere thanks to our investors for their ongoing support and belief in the Company's strategy.

Today's resolutions — governance, alignment and strategic flexibility

The resolutions brought forward today are focused on strengthening Neurizon's governance foundations, maintaining strong alignment between the Board, management and shareholders, and ensuring the Company has the flexibility required to support execution of its strategy. They include routine governance matters, approvals that reinforce confidence and alignment through Board and management participation, and measures that preserve capital flexibility and modernise our corporate framework to reflect current regulatory standards.

Thank you for your continued confidence in Neurizon. We have a bright future ahead, and your support and involvement are integral to our journey ahead.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:

Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited